GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, CTLA-4, TIGIT, TIM-3, GITR, PD-L1, B7-H3, TLR2 and TLR4.

Read the full press release.

GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif.

Read the full press release.

GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming issue.

Read the full press release.

GigaGen closes $50M deal with Grifols

,

GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols.

Read the full story from Endpoints:

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies

,

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.

Read the full press release.

GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies

,

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development of oncology drugs from mouse and human B cell repertoires using GigaGen’s novel massively parallel drug discovery technology.

Read the full press release.

GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio

,

Listen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.

GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium

,

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in California. The presentation titled “Copying and Mining Complete Immune Systems” will take place at 9:00am Pacific time, on Friday, October 7, 2016.

Read the full press release.

 

 

GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells

,

GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the use of autologous TIL to fight a range of cancers.

Read the full press release.

GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)

,

GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain.

For details of the presentation read the full press release.